임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
29건 표시
- 1/2상모집 예정· Myeloma MultipleEtenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
협력: 애브비, 사노피
- 1/2상모집 예정· Acute Lymphoblastic LeukemiaHEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
협력: 애브비, 아스트라제네카
- 1/2상모집 예정· JAK1 GOFUpadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
협력: 애브비
- 1/2상모집 중· Peripheral T Cells Lymphoma (PTCL)A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
협력: 애브비, BMS
- 1/2상모집 중· Multiple MyelomaA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
리드: 애브비
- 1/2상모집 중· Recurrent Diffuse Large B-Cell LymphomaEpcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
협력: 애브비
- 1/2상모집 중· Non Small Cell Lung CarcinomaStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
리드: 애브비
- 1/2상모집 중· Immunoglobulin Light Chain (AL) AmyloidosisA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
리드: 애브비
- 1/2상모집 중단 (진행 중)· Untreated Myelodysplastic SyndromeOral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
협력: 애브비, BMS
- 1/2상모집 중단 (진행 중)· Refractory Acute Lymphoblastic LeukemiaTrial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
협력: 애브비
- 1/2상모집 중· Acute Biphenotypic LeukemiaVenetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
협력: 애브비
- 1/2상모집 중단 (진행 중)· Relapsed/Refractory Chronic Lymphocytic LeukemiaSafety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
협력: 애브비, 일라이 릴리
- 1/2상모집 중단 (진행 중)· Open-angle GlaucomaAGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
리드: 애브비
- 1/2상모집 중단 (진행 중)· Diffuse Large B-Cell LymphomaSafety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
협력: 애브비
- 1/2상모집 중단 (진행 중)· Diffuse Large B Cell LymphomaTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
협력: 애브비
- 1/2상모집 중단 (진행 중)· Acute Myeloid LeukemiaIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
리드: 애브비
- 1/2상모집 중단 (진행 중)· Multiple MyelomaA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
리드: 애브비
- 1/2상모집 중단 (진행 중)· DLBCLFirst-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
협력: 애브비
- 1/2상모집 중단 (진행 중)· Blastic Plasmacytoid Dendritic Cell NeoplasmStudy of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
리드: 애브비
- 1/2상모집 중단 (진행 중)· Breast NeoplasmsTrial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
협력: 애브비
- 1/2상모집 중단 (진행 중)· LeukemiaVenetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
협력: 애브비
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.